Literature DB >> 27116466

Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties.

Jan Willem van der Laan1, Peter Kasper2, Beatriz Silva Lima3, David R Jones4, Markku Pasanen5.   

Abstract

Predicting the outcome of life-time carcinogenicity studies in rats based on chronic (6-month) toxicity studies in this species is possible in some instances. This should reduce the number of such studies and hence have a significant impact on the total number of animals used in safety assessment of new medicines. From a regulatory perspective, this should be sufficient to grant a waiver for a carcinogenicity study in those cases where there is confidence in the outcome of the prediction. Pharmacological properties are a frequent key factor for the carcinogenic mode of action of some pharmaceuticals, but data-analysis on a large dataset has never been formally conducted. We have conducted an analysis of a dataset based on the perspective of the pharmacology of 255 compounds from industrial and regulatory sources. It is proposed that a pharmacological, class-specific, model may consist of an overall causal relationship between the pharmacological class and the histopathology findings in rats after 6 months treatment, leading to carcinogenicity outcome after 2 years. Knowledge of the intended drug target and pathway pharmacology should enhance the prediction of either positive or negative outcomes of rat carcinogenicity studies. The goal of this analysis is to review the pharmacological properties of compounds together with the histopathology findings from the chronic toxicity study in rodents in order to introduce an integrated approach to estimate the risk of human carcinogenicity of pharmaceuticals. This approach would allow scientists to define conditions under which 2-year rat carcinogenicity studies will or will not add value to such an assessment. We have demonstrated the possibility of a regulatory waiver for a carcinogenicity study in rats, as currently discussed in the International Council for Harmonization (ICH) - formerly known as the International Conference on Harmonization (ICH), by applying the proposed prediction approach in a number of case studies.

Entities:  

Keywords:  Carcinogenicity; NEGCARC paradigm; human pharmaceuticals; pharmacology; regulatory assessment

Mesh:

Substances:

Year:  2016        PMID: 27116466     DOI: 10.3109/10408444.2016.1163664

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  5 in total

Review 1.  Goodbye to the bioassay.

Authors:  Jay I Goodman
Journal:  Toxicol Res (Camb)       Date:  2018-02-06       Impact factor: 3.524

2.  A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.

Authors:  Carole L Yauk; Alison H Harrill; Heidrun Ellinger-Ziegelbauer; Jan Willem van der Laan; Jonathan Moggs; Roland Froetschl; Frank Sistare; Syril Pettit
Journal:  Regul Toxicol Pharmacol       Date:  2019-11-11       Impact factor: 3.271

Review 3.  Prediction of the Carcinogenic Potential of Human Pharmaceuticals Using Repeated Dose Toxicity Data and Their Pharmacological Properties.

Authors:  Jan Willem van der Laan; Wenny H W Buitenhuis; Laura Wagenaar; Ans E M F Soffers; Eugene P van Someren; Cyrille A M Krul; Ruud A Woutersen
Journal:  Front Med (Lausanne)       Date:  2016-10-14

4.  Moving forward in carcinogenicity assessment: Report of an EURL ECVAM/ESTIV workshop.

Authors:  Raffaella Corvi; Federica Madia; Kathryn Z Guyton; Peter Kasper; Ruthann Rudel; Annamaria Colacci; Jos Kleinjans; Paul Jennings
Journal:  Toxicol In Vitro       Date:  2017-09-12       Impact factor: 3.500

5.  3S - Systematic, systemic, and systems biology and toxicology.

Authors:  Lena Smirnova; Nicole Kleinstreuer; Raffaella Corvi; Andre Levchenko; Suzanne C Fitzpatrick; Thomas Hartung
Journal:  ALTEX       Date:  2018       Impact factor: 6.043

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.